• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Petra Acquisition, Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    10/19/21 5:23:21 PM ET
    $PAIC
    Business Services
    Finance
    Get the next $PAIC alert in real time by email
    0001810560 false 0001810560 2021-10-13 2021-10-13 0001810560 PAIC:UnitsEachConsistingOfOneShareOfCommonStockAndOnehalfOfOneRedeemableWarrantMember 2021-10-13 2021-10-13 0001810560 PAIC:CommonStockParValue0.001PerShareMember 2021-10-13 2021-10-13 0001810560 PAIC:RedeemableWarrantsEachExercisableForShareOfCommonStockAtExercisePriceOf11.50PerShareMember 2021-10-13 2021-10-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): October 19, 2021 (October 13, 2021)

     

    PETRA ACQUISITION, INC.

    (Exact Name of Registrant as Specified in Charter)

     

    Delaware   001-39603   84-3898466
    (State or Other Jurisdiction   (Commission File Number)   (IRS Employer
    of Incorporation)       Identification No.)

     

    5 West 21st Street New York, NY 10010

    (Address of Principal Executive Offices) (Zip Code)

     

    (971) 622-5800

    (Registrant’s Telephone Number, Including Area Code)

     

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

      ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

      ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

      ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

      ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Units, each consisting of one share of common stock and one-half of one redeemable warrant   PAICU   The Nasdaq Stock Market LLC
    Common stock, par value $0.001 per share   PAIC   The Nasdaq Stock Market LLC
    Redeemable warrants, each exercisable for a share of common stock at an exercise price of $11.50 per share   PAICW   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

    Item 1.01. Entry into a Material Definitive Agreement.

     

    The information included in Item 8.01 of this Current Report on Form 8-K is also incorporated by reference into this Item 1.01 of this Current Report on Form 8-K to the extent required.

     

    Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

     

    The information included in Item 8.01 of this Current Report on Form 8-K is also incorporated by reference into this Item 2.03 of this Current Report on Form 8-K to the extent required. 

     

    Item 8.01 Other Events

     

    As previously disclosed, on September 17, 2021, Petra Acquisition, Inc. (“Petra”) issued to Pine Valley Investments, LLC (“Pine Valley”), an affiliate of Petra’s sponsor, a certain promissory note dated September 17, 2021 (the “Pine Valley Note”).

    There having been no advances made by Pine Valley to Petra under the Pine Valley Note, Petra and Pine Valley entered into that certain note cancellation agreement, dated as of October 13, 2021 (the “Note Cancellation Agreement”), pursuant to which the Pine Valley Note was terminated and cancelled effective as of October 13, 2021.

    Also on October 13, 2021, Petra issued promissory notes (the “Replacement Notes”) to each of T3 Investments, LLC, Miro Kesic and Jared Solomon (collectively, the “New Lenders”), pursuant to which the New Lenders agreed to make certain advances to Petra in an aggregate amount of up to $750,000 (the “Loan Amounts”). Such Loan Amounts are being made for the purpose of funding a contribution of cash for each share of common stock issued in Petra’s initial public offering (the “IPO”) that was not redeemed in connection with the stockholder vote to approve the extension of the deadline for Petra to complete an initial business combination, as contemplated in the definitive proxy statement on Scheduled 14A filed by Petra with the Securities and Exchange Commission on September 24, 2021. The Replacement Notes will bear interest at the rate of 2% per month on the outstanding Loan Amounts and such amounts will be repayable by Petra to the New Lenders upon consummation of an initial business combination. Any outstanding Loan Amounts under the Replacement Notes will be forgiven if Petra is unable to consummate an initial business combination except to the extent of any funds held outside of the trust account established by Petra in connection with the IPO.

    This summary is qualified in its entirety by reference to the text of the Note Cancellation Agreement and the Replacement Notes, which are included as Exhibits 10.1, 10.2, 10.3 and 10.4 to this Current Report on Form 8-K and are incorporated herein by reference. 

     

    Item 9.01. Financial Statements and Exhibits

     

    (c) Exhibits:

     

    Exhibit No.   Description
    10.1   Note Cancellation Agreement by and between the Registrant and Pine Valley Investments, LLC
    10.2   Promissory Note, dated as of October 13, 2021 from the Registrant to T3 Investments, LLC
    10.3   Promissory Note, dated as of October 13, 2021 from the Registrant to Miro Kesic
    10.4   Promissory Note, dated as of October 13, 2021 from the Registrant to Jared Solomon

     

    1

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Dated: October 19, 2021

     

      PETRA ACQUISITION, INC.
         
      By: /s/ Andreas Typaldos
      Name:  Andreas Typaldos
      Title: Chairman & Chief Executive Officer

     

     

    2

     

     

    Get the next $PAIC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PAIC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PAIC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Revelation Biosciences Inc. Receives Approval to Initiate Phase 2b Viral Challenge Study of REVTx 99, an Experimental Prophylactic Treatment for the Prevention of Respiratory Viral Infections

    - Phase 2b study will investigate the efficacy of REVTx-99 on viral load and patient-reported flu symptoms- - Top-line data anticipated in the second quarter of 2022 - SAN DIEGO, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (Revelation), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, announced today it has received approval from the Federal Agency for Medicines and Health Products (FAMHP) and the local Committee of Medical Ethics in Belgium to conduct a Phase 2b influenza viral challenge study. The Phase 2b, randomized, double-blind, influenza viral challenge study (RV

    9/28/21 9:00:00 AM ET
    $PAIC
    Business Services
    Finance

    Revelation Biosciences, Inc., a Life Sciences Company Developing Therapeutics and Diagnostics for Respiratory Viral Infections, Including COVID-19, to Become Publicly Traded Through a Merger with Petra Acquisition, Inc.

    Revelation's lead product candidate REVTx-99 has potential, through innate immune system stimulation, to broadly prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2 including its variants, influenza A and B, parainfluenza, rhinovirus, and respiratory syncytial virus (RSV) Combined company expected to have a post-transaction pro forma total enterprise value of approximately $128 million Merger expected to close in Q4 2021, and combined company will be listed on NASDAQ under the ticker symbol "REVB" Revelation and Petra Acquisition will host a joint investor conference call and webcast to discuss the proposed transaction on August 30, 2021 at 4:30 p.m

    8/30/21 6:00:00 AM ET
    $PAIC
    Business Services
    Finance

    PETRA ACQUISITION, INC. RECEIVES EXPECTED NASDAQ NOTIFICATION REGARDING DELAYED FORM 10-Q

    New York, NY, June 01, 2021 (GLOBE NEWSWIRE) -- Petra Acquisition, Inc. (NASDAQ:PAIC) (the "Company"), a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities, announced that on May 28, 2021, it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq") advising that because the Company failed to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2021 (the "Form 10-Q"), the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule"). Nasdaq has inform

    6/1/21 4:30:00 PM ET
    $PAIC
    Business Services
    Finance

    $PAIC
    SEC Filings

    View All

    Petra Acquisition, Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits, Unregistered Sales of Equity Securities, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Change in Shell Company Status

    8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)

    1/14/22 4:28:56 PM ET
    $PAIC
    Business Services
    Finance

    Petra Acquisition, Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)

    1/13/22 3:53:16 PM ET
    $PAIC
    Business Services
    Finance

    Petra Acquisition, Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)

    1/12/22 4:49:37 PM ET
    $PAIC
    Business Services
    Finance

    $PAIC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Feis Lawrence disposed of $7,465,890 worth of shares (731,950 units at $10.20)

    4 - Petra Acquisition Inc. (0001810560) (Issuer)

    1/11/22 3:59:54 PM ET
    $PAIC
    Business Services
    Finance

    SEC Form 3: New insider Feis Lawrence claimed ownership of 746,491 shares

    3 - Petra Acquisition Inc. (0001810560) (Issuer)

    11/2/21 2:39:14 PM ET
    $PAIC
    Business Services
    Finance

    SEC Form 4: Glazer Capital, Llc sold $6,597,824 worth of Common stock (654,546 units at $10.08)

    4 - Petra Acquisition Inc. (0001810560) (Issuer)

    9/23/21 4:21:06 PM ET
    $PAIC
    Business Services
    Finance

    $PAIC
    Financials

    Live finance-specific insights

    View All

    Revelation Biosciences, Inc., a Life Sciences Company Developing Therapeutics and Diagnostics for Respiratory Viral Infections, Including COVID-19, to Become Publicly Traded Through a Merger with Petra Acquisition, Inc.

    Revelation's lead product candidate REVTx-99 has potential, through innate immune system stimulation, to broadly prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2 including its variants, influenza A and B, parainfluenza, rhinovirus, and respiratory syncytial virus (RSV) Combined company expected to have a post-transaction pro forma total enterprise value of approximately $128 million Merger expected to close in Q4 2021, and combined company will be listed on NASDAQ under the ticker symbol "REVB" Revelation and Petra Acquisition will host a joint investor conference call and webcast to discuss the proposed transaction on August 30, 2021 at 4:30 p.m

    8/30/21 6:00:00 AM ET
    $PAIC
    Business Services
    Finance

    $PAIC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Petra Acquisition, Inc. (Amendment)

    SC 13G/A - Petra Acquisition Inc. (0001810560) (Subject)

    1/11/22 3:34:57 PM ET
    $PAIC
    Business Services
    Finance

    SEC Form SC 13G/A filed by Petra Acquisition, Inc. (Amendment)

    SC 13G/A - Petra Acquisition Inc. (0001810560) (Subject)

    10/12/21 4:02:40 PM ET
    $PAIC
    Business Services
    Finance

    SEC Form SC 13G/A filed by Petra Acquisition, Inc. (Amendment)

    SC 13G/A - Petra Acquisition Inc. (0001810560) (Subject)

    10/12/21 10:33:03 AM ET
    $PAIC
    Business Services
    Finance